Methods for identifying target nucleic acids

By employing a simultaneous multiplex real-time PCR method and using a variety of fluorescently labeled probes and primer combinations, the limitations of fluorescence wavelength in existing technologies have been overcome, enabling efficient and accurate detection of multiple target nucleic acids, particularly pathogenic variants of citric acid deficiency, at a single fluorescence wavelength.

CN123125342APending Publication Date: 2026-11-17SEKISUI MEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580027824.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-06-26
Filing Date
2025-05-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing real-time PCR technology has limited fluorescence wavelengths when detecting multiple target nucleic acids, making it difficult to perform multiplex assays of more than five at the same time. This is especially true when detecting diseases with a large number of pathogenic variants, such as citric acid deficiency, where existing methods are cumbersome and not accurate enough.

Method used

Simultaneous multiplex real-time PCR was employed, using a variety of fluorescently labeled probes and primer combinations. By setting different Ct values ​​and fluorescence value ranges, multiple target nucleic acids were identified at the same fluorescence wavelength. This included designing fluorescently labeled probes to modify the ends of the target nucleic acids and comparing them within non-overlapping Ct and fluorescence value ranges.

Benefits of technology

This technology enables the simultaneous detection of multiple target nucleic acids at a single fluorescence wavelength, and is particularly effective in identifying pathogenic variants of diseases such as citric acid deficiency. It simplifies the operation process and improves the accuracy and efficiency of detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention provides a method for identifying target nucleic acids, which can easily identify multiple target nucleic acids simultaneously at a single fluorescence wavelength. This method is also useful for detecting diseases with numerous pathogenic variants, such as citric acid deficiency. The method for identifying target nucleic acids of this invention includes: step (a) below; and steps (b) to (c) and / or (d) to (e) below, wherein the method identifies two or more target nucleic acids contained in a sample via simultaneous multiplex real-time PCR. (a) A step of contacting the sample, primer set, and fluorescently labeled probe to amplify the target nucleic acids in the sample; (b) A step of generating an amplification curve based on step (a) and obtaining a Ct value from a set threshold; (c) A step of comparing the set Ct value for each target nucleic acid with the Ct value obtained in step (b); (d) A step of generating an amplification curve based on step (a) and obtaining a fluorescence value within a set number of cycles; (e) A step of comparing the fluorescence value within a set number of cycles for each target nucleic acid with the fluorescence value obtained in step (d).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a method for identifying target nucleic acids. Background Technology

[0002] As a representative detection method for disease-related target nucleic acids, real-time PCR using fluorescently labeled probes is known (see Patent Document 1 and Patent Document 2).

[0003] One type of device capable of applying real-time PCR is the commercially available "LightCycler 96 system" (Roche), which allows for a combination of up to four fluorescence assays using four filters. As a newborn screening procedure, the inventors have envisioned genetic testing for, for example, primary immunodeficiency and spinal muscular atrophy, and have constructed a simultaneous multiplex assay system that detects a total of four genes simultaneously using four fluorescence assays: TREC, KREC, and SMN1 (as desired genes), plus ribonuclease P (called RNase P) as an internal standard gene (see Patent Document 1, etc.).

[0004] Existing technical documents Patent documents Patent Document 1: Japanese Patent No. 6761093 Patent Document 2: Japanese Patent No. 7063886 Summary of the Invention

[0005] The technical problem that the invention aims to solve In real-time PCR using fluorescently labeled probes, theoretically one fluorescent substance is selected for each target nucleic acid. Therefore, when detecting multiple target nucleic acids, the variety of fluorescence wavelengths available on the device is limited, which restricts the application of multiplex assays that simultaneously detect multiple target nucleic acids in a single amplification reaction.

[0006] Furthermore, as mentioned above, the inventors have constructed a simultaneous multiplex assay system for detecting four genes using four different fluorescence assays. Due to the necessity of early diagnosis and treatment in both of the aforementioned diseases, this system is being widely adopted in Japan as an expanded screening method for newborns. On the other hand, among the congenital metabolic disorders identified in current large-scale newborn screenings funded by the Japanese government, some diseases, such as citrin deficiency, have a high rate of false negatives, making screening based on metabolite measurement unsatisfactory. Among these diseases, there are also those with identified pathogenic genes that contribute to the onset of the disease. For example, it has been reported that in citrin deficiency, pathogenic variants of the SLC25A13 gene (also known as pathogenic mutations) are associated with the onset of the disease. There are many pathogenic variants of this disease, but as a variant that is particularly prevalent in the Japanese population, there are six known variants with high allele frequencies, covering more than 90%. Therefore, it is envisioned to detect the presence of pathogenic gene variants in newborn screening. However, the current situation is that the fluorescence wavelength is limited in general thermal cycler equipment used for real-time PCR, making it difficult to perform multiplex testing on more than five target genes at once.

[0007] In Patent Document 2, multiple oligonucleotide probes labeled with the same fluorescent dye molecule and having different Tm (melting temperature) values ​​for their non-complementary tag portions and quenchers can be used to detect multiple target nucleic acids with a single fluorescent dye. However, specific features are required in the design of the tag portions and quenchers of the probe oligonucleotides. In addition, in order to obtain the calculated signal, a process of subtracting the signals obtained at different Tm temperatures is required, which involves complex operations.

[0008] The present invention was made in view of the above-mentioned situation, and its purpose is to provide a method for identifying target nucleic acids, that is, to be able to identify multiple target nucleic acids simultaneously at one fluorescence wavelength in a relatively easy way, which is also useful for the examination of diseases with a large number of pathogenic variants, such as citric acid deficiency.

[0009] Technical solutions for solving technical problems This invention 1 is a method for identifying target nucleic acids, comprising: the following step (a); and the following steps (b) to (c) and / or (d) to (e), wherein the above-mentioned identification method identifies two or more target nucleic acids contained in a sample by simultaneous multiplex real-time PCR. (a) A process of bringing the above-mentioned sample, primer set and fluorescently labeled probe into contact to amplify the above-mentioned target nucleic acid in the above-mentioned sample; (b) The process of creating an amplification curve based on the above step (a) and obtaining the Ct value from a set threshold; (c) A process of comparing the Ct value set for each of the above target nucleic acids with the Ct value obtained in step (b) above; (d) The process of generating an amplification curve based on the above step (a) to obtain fluorescence values ​​within a set number of cycles; (e) A process of comparing the fluorescence value within the set number of cycles for each of the target nucleic acids with the fluorescence value obtained in step (d) above.

[0010] The present invention 2 is the discrimination method of the present invention 1, wherein the discrimination method uses two or more primer sets (1) as the primer sets, the primer sets (1) comprising a forward primer and a reverse primer, and / or uses one or more primer sets (2) as the primer sets, the primer sets (2) comprising at least one of two or more forward primers and reverse primers, and one or more of the other.

[0011] The 3rd invention is the discrimination method of the 2nd invention, wherein the discrimination method uses two or more primer sets (1) as primer sets and uses two or more fluorescently labeled probes labeled with the same fluorescent label as fluorescently labeled probes.

[0012] The present invention 4 is the discrimination method of the present invention 2, wherein the discrimination method uses one or more of the above primer sets (2) as the above primer sets, and uses one or more fluorescently labeled probes as the above fluorescently labeled probes.

[0013] This invention 5 is a method for determining any one of the claims 1 to 4 of this invention, wherein the above-mentioned step (a) is performed in the same container.

[0014] The present invention 6 is a discrimination method of any one of the present inventions 1 to 5, wherein the fluorescently labeled probe is designed to modify the two ends of the target nucleic acids or to clamp the target nucleic acids.

[0015] The present invention 7 is a discrimination method of any one of the present inventions 1 to 6, wherein, when setting the Ct value of each of the above target nucleic acids in the above step (c), the difference between the center values ​​of each Ct value range under the same template amount is 5 or more, and the Ct value ranges do not overlap.

[0016] The present invention 8 is a discrimination method of any one of the present invention 1 to 7, wherein, in the above step (e), when setting the fluorescence value within the set number of cycles for each of the above target nucleic acids, the ratio of the center values ​​of each fluorescence value range is more than 1.4 times, and the fluorescence value ranges under the set number of cycles do not overlap.

[0017] The present invention 9 is a discrimination method of any one of the present inventions 1 to 8, wherein the above-mentioned two or more target nucleic acids include at least one selected from the combination of gene variants that are different from each other, including deletion mutations, insertion mutations and point mutations, and the combination of a first gene variant and the wild type of the first gene variant.

[0018] The present invention 10 is a method for judging any one of the present inventions 1 to 9, wherein the sample used in the above-mentioned step (a) is a sample of a slice of blood from filter paper without pretreatment, and the blood from filter paper is obtained by drying after the filter paper contains blood.

[0019] The present invention 11 is a discrimination method of any one of the present inventions 1 to 10, wherein the fluorescently labeled probe has a fluorescent substance site and a quencher site, and contains a partial sequence complementary to the template of the nucleic acid amplification reaction, and the discrimination method detects the amplified target nucleic acid by detecting the fluorescence generated by irradiating the fluorescent substance site with excitation light.

[0020] The present invention will now be described in detail.

[0021] Invention Effects According to the present invention, a method for identifying target nucleic acids (e.g., a method for identifying gene variants) can be provided, which can detect multiple target nucleic acids simultaneously at a single fluorescence wavelength in a relatively easy manner, and is also useful for the examination of diseases with a large number of pathogenic variants, such as citric acid deficiency. Attached Figure Description

[0022] Figure 1 This is the amplification curve of the fluorescent dye Cy5 at the fluorescence wavelength (Example 1).

[0023] Figure 2 This is the amplification curve of the fluorescent dye Red610 at the fluorescence wavelength (Example 2).

[0024] Figure 3 This is the amplification curve of the fluorescent dye Cy5 at the fluorescence wavelength (Example 3).

[0025] Figure 4 This is the amplification curve of the fluorescent dye Red610 at the fluorescence wavelength (Example 4).

[0026] Figure 5 This is the amplification curve of the fluorescent dye Hex at the fluorescence wavelength (Example 5).

[0027] Figure 6 This is the amplification curve of the fluorescent dye Hex at the fluorescence wavelength (Example 6).

[0028] Figure 7 This is the amplification curve of the fluorescent dye Red610 at the fluorescence wavelength (Example 7).

[0029] Figure 8 The amplification curve of the fluorescent dye Hex obtained in Example 8 is shown at the fluorescence wavelength.

[0030] Figure 9 The amplification curve of the fluorescent dye Red610 obtained in Example 8 at the fluorescence wavelength is shown. Detailed Implementation

[0031] (Explanation of terminology) In this specification, "nucleic acid" refers to a polymer of nucleotides (polynucleotides). Nucleotides are ribonucleotides in RNA and deoxyribonucleotides in DNA, and can be either natural or unnatural. Examples of nucleic acids include DNA and RNA (including hypodural cDNA, mRNA, etc.). Nucleic acids can be single-stranded or double-stranded.

[0032] "Target nucleic acid" refers to the nucleic acid or region thereof selected for extension, replication, amplification, and detection. The target nucleic acid is present in the sample before amplification. It should be noted that the product of amplifying the target nucleic acid via PCR is called the "amplification product." By amplifying the target nucleic acid, a new nucleic acid sequence is integrated into the amplification product. The added nucleic acid sequence is part of the amplification product.

[0033] A primer is an oligonucleotide with a base sequence complementary to the target nucleic acid, serving as a starting point for extension. Oligonucleotides are short polynucleotides, with chain lengths ranging from 1 to 200. Primers are typically single-stranded nucleic acids, for example, having a first part complementary to and hybridizing with the target nucleic acid and a second part complementary to and hybridizing with the probe. A set (pair) of primers configured to clamp the region to be amplified is called a "primer set." A primer set typically contains a forward primer and a reverse primer.

[0034] A "probe" is a labeled oligonucleotide that forms a double-stranded structure with the target nucleic acid sequence through complementarity with at least a portion of the target nucleic acid sequence. For example, a probe hybridizes with the second part of a primer through complementarity of its sequence with the second part of the primer sequence. Probes labeled with fluorescent substances are called "fluorescently labeled probes."

[0035] "Real-time PCR" is a method in PCR (polymerase chain reaction) that monitors (detects) the amplification process (i.e., the generation of amplification products) in real time. The method of simultaneously detecting multiple target nucleic acids through a single amplification reaction (PCR reaction) in real-time PCR is called "simultaneous multiplex real-time PCR".

[0036] In real-time PCR, fluorescent substances are used to monitor the amplification process. The resulting curve, plotted with the X-axis representing the cycle number of the amplification reaction (also called the reaction cycle number) and the Y-axis representing the fluorescence value based on the amplification reaction (also called the fluorescence signal), is called the "amplification curve." Depending on the thermal cycler equipment, the fluorescence signal is sometimes expressed in relative fluorescence units (RFU). The "Ct value (Threshold cycle)" represents the number of cycles at which amplification products reach a certain amount (threshold), and is sometimes also labeled as the "Cq value (Quantification cycle)." That is, the Ct value (Cq value) is the number of cycles at which the amplification curve intersects the threshold.

[0037] (Methods for identifying target nucleic acids) The discrimination method of the present invention is a method for identifying two or more target nucleic acids contained in a sample by simultaneous multiplex real-time PCR.

[0038] The above-mentioned discrimination method includes: the following process (a); and the following processes (b) to (c) and / or the following processes (d) to (e). That is, the above-mentioned discrimination method is any one of the following processes (a) to (c), the following processes (a) to (e), or the following processes (a), (d), and (e), and may further include one or more other processes.

[0039] (a) A process of bringing the sample, primer set and fluorescently labeled probe into contact to amplify the target nucleic acid in the sample.

[0040] (b) The process of creating an amplification curve based on the above step (a) and obtaining the Ct value from a set threshold.

[0041] (c) A process of comparing the Ct value set for each target nucleic acid with the Ct value obtained in step (b) above.

[0042] (d) The process of generating an amplification curve based on the above step (a) to obtain the fluorescence value at the set number of cycles.

[0043] (e) A process of comparing the fluorescence value at the set number of cycles for each target nucleic acid with the fluorescence value obtained in step (d) above.

[0044] The above-described step (b) is performed after the following step (a), and the above-described step (c) is performed after the above-described step (b). Furthermore, the above-described step (d) is performed after the following step (a), and the above-described step (e) is performed after the above-described step (d). When the above-described determination method includes the above-described steps (a) to (e), either the above-described step (b) or the above-described step (d) may be performed first or simultaneously.

[0045] <Process (a)> The substances other than the sample used in the PCR reaction are called "PCR reagents". In addition to primer sets and fluorescently labeled probes, the PCR reagents used in step (a) may also include, for example, polymerase and buffer. The buffer is not particularly limited as long as it has the function of inhibiting positively charged substances (such as certain proteins) and negatively charged substances (such as certain sugars and pigments) present in the body fluids of organisms that hinder DNA amplification reactions.

[0046] The above-described step (a) is preferably performed in the same container, for example. A tube (also called a PCR reaction tube) is preferably used as the container. The above-described step (a) preferably includes, for example, an addition step of adding the sample and PCR reagents to the PCR reaction tube; a reaction step of performing the PCR reaction while the tube is sealed; and a detection step of detecting the amplified product amplified by the PCR reaction over time while the sample is present in the tube.

[0047] (Add a process) The sample supplied for step (a) above is a sample suspected of containing two or more target nucleic acids. The sample is preferably blood, and more preferably blood in filter paper that has been dried after containing blood in filter paper. Examples of samples include filter paper blood collected from the heels of newborns in large-scale newborn screening, and filter paper blood collected as an optional screening, but are not limited to these. Hereinafter, "filter paper blood that has been dried after containing blood in filter paper" will also be simply referred to as "dried filter paper blood".

[0048] For the aforementioned dried blood filter paper, the filter paper is dried after containing blood, and then a perforated sheet (hereinafter referred to as "perforated sheet") is taken out using a perforator. The size of the perforated sheet cut from the dried blood filter paper needs to be within an appropriate range of the amount of blood contained, therefore a diameter of 1.2 mm to 2.0 mm is preferred, and 1.5 mm to 1.8 mm is more preferred. In addition, the amount of whole blood contained in the perforated sheet is preferably 0.95 v / v% to 6.6 v / v% relative to the total PCR reaction solution volume, and more preferably 1.4 v / v% to 5.2 v / v%. In the above step (A), it is particularly preferred that the nucleic acid sample is dried blood filter paper, which is made by containing whole blood in the filter paper and then drying it, and that the filter paper is a circular perforated sheet with a diameter of 1.2 mm to 2.0 mm and containing 0.95 v / v% to 6.6 v / v% of whole blood relative to the total reaction solution volume.

[0049] The preferred sample is a slice of blood from filter paper (dried blood from filter paper), which is prepared by directly using filter paper containing blood and then drying it without pretreatment. In untreated samples, substances that typically inhibit DNA amplification reactions include, for example, hemoglobin present in the blood, and precipitates of blood components caused by heat denaturation during PCR. However, if the aforementioned perforated slice is used as the sample, and the PCR reaction is performed with the PCR reaction tube sealed with a cap, the precipitates of blood components and the floating (bulging) of the perforated slice itself can be sufficiently suppressed. Therefore, without affecting fluorescence measurement, and without the need for complex pretreatment such as separation and purification from dried blood from filter paper, the blood from filter paper can be directly used for the PCR reaction.

[0050] In step (a) above, at least one primer set is used. In particular, in step (a) above, it is preferable to use two or more primer sets (1) or one or more primer sets (2) as primer sets.

[0051] Primer set (1): A primer set containing one forward primer and one reverse primer.

[0052] Primer set (2): A primer set containing at least one of two or more forward primers and one or more of the other.

[0053] As a method of using two or more primer sets (1) mentioned above, specifically, it is possible to use two or more primer sets corresponding to two or more target nucleic acids that are to be discriminated against. That is, the two or more primer sets preferably include a first primer set and a second primer set whose corresponding target nucleic acids are different from each other.

[0054] Examples of the primer set (2) mentioned above include a primer set containing two forward primers and one reverse primer (i.e., a common reverse primer) and a primer set containing two reverse primers and one forward primer (i.e., a common forward primer).

[0055] Using one or more primer sets (2) as described above is suitable for situations where a gene variant (also called a "first gene variant") and the wild type of the first gene variant are used as the distinguishing objects. In this case, when using primer set (2) as described above, for example, a primer set containing two forward primers and a common reverse primer, the common reverse primer can be used as a reverse primer for the first gene variant and also as a reverse primer for the wild type.

[0056] The optimal capacity molar concentration (final concentration) for each primer set is 0.1. m M~1.0 m M, more preferably 0.2 m M~0.5 m M.

[0057] When using two or more primer sets (1) in step (a) above, it is preferable to use two or more fluorescently labeled probes that are labeled with the same fluorescent substance as each other as fluorescently labeled probes. Specifically, probes that correspond to two or more target nucleic acids that are to be identified and are labeled with the same fluorescent substance as each other are used. For example, it is preferable that the two or more fluorescently labeled probes include a first probe and a second probe that correspond to different target nucleic acids, and these first probes and second probes are labeled with the same fluorescent substance as each other.

[0058] When using one or more primer sets (2) in step (a) above, it is preferable to use one or more fluorescently labeled probes as fluorescently labeled probes. For example, when the first gene variant and the wild type of the first gene variant are the objects of discrimination, if one fluorescently labeled probe is used, the fluorescently labeled probe can be used as a probe for the first gene variant and also as a probe for the wild type.

[0059] The preferred final concentration (molar concentration) of each fluorescently labeled probe is 0.01. m M~0.3 m M, more preferably 0.03 m M~0.15 m M.

[0060] Preferably, each fluorescently labeled probe is designed to hold the target nucleic acid. That is, each fluorescently labeled probe preferably modifies both ends of the target nucleic acid, more preferably by modifying both ends of the target nucleic acid with a fluorescent substance and a quencher, respectively, and even more preferably has both a fluorescent substance site and a quencher site, and includes a partial sequence complementary to the template for the nucleic acid amplification reaction. When using such fluorescently labeled probes, in the discrimination method of the present invention, the amplified target nucleic acid can be detected by detecting the fluorescence generated by irradiating the fluorescent substance site with excitation light. It should be noted that the fluorescent substance site refers to the site modified by the fluorescent substance, and the quencher site refers to the site modified by the quencher. The aforementioned fluorescently labeled probes particularly preferably have a fluorescent substance site at the 5' end and a quencher site at the 3' end of the target nucleic acid.

[0061] Examples of fluorescent substances include Quasar (registered trademark) 670, CAL Fluor (registered trademark) Orange 560, CAL Fluor (registered trademark) Red 610, FAM (e.g., 5-carboxyfluorescein, 6-carboxyfluorescein), Cy3, Cy5, etc. Examples of quenchers include BHQ (registered trademark)-1, BHQ (registered trademark)-2, etc. It should be noted that they can be purchased from companies such as LGC Biosearch Technologies.

[0062] In step (a) above, when using two or more primer sets, it is preferable to set the capacity molar concentration (final concentration) of each primer constituting one primer set to be different from the capacity molar concentration of each primer constituting other primer sets, or when using two or more fluorescently labeled probes, set the capacity molar concentration (final concentration) of one of the fluorescently labeled probes to be different from the capacity molar concentration of the other fluorescently labeled probes. This makes it easier to simultaneously detect multiple target nucleic acids with a single fluorescence wavelength.

[0063] It should be noted that the capacity molar concentration (concentration) of each primer and the capacity molar concentration (final concentration) of the fluorescently labeled probe can be set by considering, for example, the Ct value of each target nucleic acid.

[0064] In step (a) above, the amount (total amount) of PCR reagent added to the PCR reaction tube is preferably, for example, 20g. m L~50 m L. In the above-described addition process, PCR reagents can be added after the sample is added to the PCR reaction tube, after the PCR reagents are added, or simultaneously. However, it is preferable to add the PCR reagents after the sample is added to the PCR reaction tube. It is also preferable to perform centrifugation before the PCR reaction begins.

[0065] (Reaction process) The PCR reaction tubes preferably have a perforated flap with filter paper that allows for smooth insertion and a sealed cap. Furthermore, the shape of the PCR reaction tubes is preferably a circular opening at the top (e.g., an inner diameter of approximately 2.5 mm to 10 mm) with a bottom narrower than the top opening; an inverted conical shape is more preferred. The capacity of the PCR reaction tubes should be sufficient to accommodate the added PCR reagents, taking into account temperature changes during the PCR reaction; for example, 0.1 mL to 0.3 mL is preferred, 0.15 mL to 0.25 mL is more preferred, and 0.2 mL is most preferred.

[0066] The tubes used for PCR reactions are preferably 96-well tubes of 96 consecutive tubes or 8 consecutive tubes of 8. The material of the reaction tubes is preferably one that minimizes contamination by the reaction solution and has rigidity that does not change shape even when the internal pressure changes due to temperature variations in the PCR reaction; for example, polypropylene.

[0067] For sealing PCR reaction tubes, caps are preferred. The cap only needs to be a structure that fits snugly into the opening of the PCR reaction tube for a tight seal. The cap material is the same as the PCR reaction tube, preferably a material that will not deform due to internal pressure changes caused by the PCR reaction. Furthermore, a material with high light transmittance is preferred; specifically, polypropylene is an example.

[0068] Temperature changes in each step of the PCR reaction can be automatically controlled, for example, using a thermal cycler. For instance, by starting the PCR reaction with a sealed tube (such as a cap), the generation of bubbles caused by temperature changes can be suppressed, the sample (preferably the perforated plate) will not float, and vibration can be suppressed.

[0069] (Inspection process) The amplification products generated by the PCR reaction can be detected (and quantified) by measuring the fluorescence intensity (fluorescence value) produced by the amplification products. Fluorescence detection preferably employs methods such as the conventionally known intercalation method, TaqMan probe method, hybridization method, and cycling probe method. Fluorescence intensity is detected, for example, by a fluorometer. Typically, it is preferable to use a device equipped with a PCR reaction unit (e.g., a thermal cycler) and an optical unit (e.g., a fluorometer). Examples of such devices include SmartCycler (trade name, manufactured by Takara Bio), LightCycler (trade name, manufactured by Roche), and ABI PRISM7000 (trade name, manufactured by Applied BioSystems).

[0070] The detection of amplification products can be performed at the end or after the PCR reaction, or it can be performed in parallel with the PCR reaction. When the amplification products are detected in parallel with the PCR reaction, the detection can be performed over time, for example. Over time detection can be performed continuously or intermittently. Furthermore, by counting the number of PCR cycles in which the amplification products reach a predetermined amount, the target nucleic acid contained in the sample can be quantified. The concentration of 1% Cq in the sample can also be calculated based on a standard curve derived from standards. m The copy number of L whole blood was quantified.

[0071] <Process (b)> The amplification reaction (PCR reaction) in step (a) above yields an amplification curve. Based on this amplification curve, the Ct value is obtained from a set threshold. The threshold is generally set to identify the amplification signal generated by the reaction from the background. It can be set at any point in the amplification phase of the exponential function of the amplification curve, but it can also be fixed depending on the equipment used, thus adhering to the equipment. For example, since the threshold is fixed in the "LightCycler 96 system" (Roche), the Ct value is obtained based on this threshold.

[0072] <Process (c)> Before step (c) above, a Ct value range is pre-defined for each target nucleic acid. For example, it is preferable to set the center value of the Ct value range for each target nucleic acid such that the difference between them under the same template amount is 5 or more, and the Ct value ranges do not overlap. That is, for example, it is preferable to set Ct1 and Ct2 such that the difference (absolute value) between the center value of the Ct value range of the first target nucleic acid (referred to as Ct1) and the center value of the Ct value range of the second target nucleic acid (referred to as Ct2) under the same template amount is 5 or more, and the Ct value ranges centered at Ct1 and Ct2 do not overlap. This makes the discrimination of target nucleic acids easier.

[0073] In step (c) above, the center value of the pre-defined Ct value range for each target nucleic acid (e.g., Ct1 and Ct2) is compared with the Ct value obtained in step (b) above.

[0074] <Process (d)> Based on the amplification curve obtained in step (a) above, in step (d), a fluorescence value is selected from the fluorescence values ​​(or RFU) within a set number of cycles. Preferably, it is the fluorescence value of the set final cycle. The fluorescence value (or RFU) selected in this way is used as the fluorescence value obtained in step (d) above.

[0075] <Process (e)> Prior to step (e) above, a fluorescence value range within a predetermined number of cycles is pre-defined for each target nucleic acid. For example, it is preferable that the ratio of the center values ​​of the fluorescence value ranges within the predetermined number of cycles for each target nucleic acid is at least 1.4 times, and that the fluorescence value ranges within the predetermined number of cycles do not overlap. That is, for example, it is preferable to set F1 and F2 such that the ratio (F1 / F2 or F2 / F1) between the center value of the fluorescence value range within the predetermined number of cycles for the first target nucleic acid (referred to as F1) and the center value of the fluorescence value range within the predetermined number of cycles for the second target nucleic acid (referred to as F2) is at least 1.4 times, and that the fluorescence value ranges centered on F1 and F2 do not overlap. In this case, the discrimination of the target nucleic acids becomes easier.

[0076] In step (e) above, the fluorescence value of each target nucleic acid at a pre-set number of cycles (e.g., F1 and F2) is compared with the fluorescence value obtained in step (d) above. For example, if the comparison in step (c) above is difficult (e.g., if it cannot be distinguished by Ct value), it is effective to perform steps (d) to (e) above based on or instead of steps (b) to (c) above.

[0077] In steps (c) and (e) above, it is particularly preferable to combine differences in the shape of the amplification curve, fluorescence intensity, and the timing of the amplification rise for the comparison. This makes it easier to identify target nucleic acids in measurements based on the same fluorescence wavelength, and also makes it easier to identify target nucleic acid complexes (complex variants, etc.). In particular, the discrimination method of the present invention is of great significance for identifying the presence of multiple target nucleic acids that differ from each other in Ct value and fluorescence value using either or a combination of both of these two factors.

[0078] The target nucleic acid identified by the discrimination method of the present invention is not particularly limited, and examples include microorganisms, complex biological mixtures, tissues, body fluids, serum, preserved biological samples, environmental isolates, and in vitro preparations. Specifically, the target nucleic acid includes not only DNA and RNA derived from whole blood, but also foreign nucleic acids introduced into whole blood via viruses or the like. Preferably, the target nucleic acid is a nucleic acid derived from the whole blood of a newborn.

[0079] In the discrimination method of the present invention, two or more target nucleic acids amplified by PCR reaction can be detected simultaneously and discriminated (also called identified) separately. In the above discrimination method, it is preferable that the two or more target nucleic acids to be discriminated include at least one selected from combinations of gene variants that are different from each other, including deletion mutations, insertion mutations, and point mutations, and combinations of any gene variant (first gene variant) and the wild type of the first gene variant. That is, for example, when the two or more target nucleic acids include two different target nucleic acids, the combination of the two target nucleic acids is preferably any one of the following: a combination of deletion mutation and insertion mutation, a combination of insertion mutation and point mutation, a combination of point mutation and deletion mutation, or a combination of the first gene variant and the wild type of the first gene variant.

[0080] It should be noted that when the two or more target nucleic acids being identified contain combinations of different gene variants, primer set (1) is preferably used in step (a) above. Furthermore, when the two or more target nucleic acids being identified contain a combination of a first gene variant and the wild-type of that first gene variant, primer set (2) is preferably used in step (a) above. When both the two or more target nucleic acids being identified contain combinations of different gene variants and combinations of a first gene variant and the wild-type of that first gene variant, primer set (1) and primer set (2) are preferably used in step (a) above. It should be noted that primer set (1) is preferably a set of forward and reverse primers for each mutation (e.g., deletion mutation, insertion mutation, and point mutation), and primer set (2) is preferably a set of forward and reverse primers for both wild-type and mutant types (e.g., deletion mutation, insertion mutation, and point mutation).

[0081] The discrimination method of the present invention is particularly useful for gene testing (e.g., screening) of diseases in which a large number of pathogenic variants exist in the pathogenic gene. Examples of such diseases include citrulline deficiency and glycogenopathies. Therefore, the target nucleic acid is particularly preferably composed of at least one pathogenic gene selected from citrulline deficiency and glycogenopathies. Preferably, the target nucleic acid contains the pathogenic gene for citrulline deficiency (SLC25A13 gene), more preferably contains two or more pathogenic variants of the SLC25A13 gene, and even more preferably contains two or more variants of type 1, type 2, type 3, type 4, type 5, and type 19 of the SLC25A13 gene.

[0082] Citrin deficiency can be diagnosed by identifying pathogenic mutations in two alleles of the SLC25A13 gene, which is the pathogenic gene. A high-frequency mutation specific to Japanese individuals has been reported as a pathogenic mutation (Ayako Tabata et al., “Identification of 13 novel mutations including aretrotransposal insertion in SLC25A13 gene and frequency of 30 mutations found in patients with citrin deficiency”, Journal of Human Genetics, 2008, Vol. 53(6), pp. 534-545). According to this report, six variants, including type 1, type 2, type 3, type 4, type 5, and type 19, account for more than 90% of the mutation frequency. For example, if the discrimination method of this invention is used in the LightCycler (registered trademark) 96 system, up to six genes, excluding the internal standard gene RNaseP, can be detected using three different fluorescent methods. Therefore, the discrimination method of the present invention is particularly useful for screening for citrulline deficiency, in which six variants account for more than 90% of the mutation frequency. The discrimination method of the present invention for genetic testing of citrulline deficiency is also one of the inventors' inventions.

[0083] Example The following examples illustrate the invention in more detail, but the invention is not limited to these examples. It should be noted that... Figure 1~Figure 9 In the diagram, the X-axis represents the reaction cycle number, and the Y-axis represents the fluorescence signal (RFU). Figure 1~Figure 9 In order to make it easier to read the diagrams, the description of cycles 1 to 19 is omitted, and only cycles 20 to 45 are shown.

[0084] <Examples 1 to Examples 8> (a) Test materials (a-1) Primers used for amplification of various variants of the SLC25A13 gene Primers used for amplification of various variants of the SLC25A13 gene and the internal standard gene (RNaseP) were obtained by having Sigma-Aldrich synthesize the following primers.

[0085] Type 1 variant with forward primer: 5'-TTTCCCCCTACAGACGACC-3' (Serial Number 1) Type 1 wild type using forward primer: 5'-CCCCTACAGAC[GTAT]GACC-3' (Sequence No. 2) ([GTAT] indicates the absence of 4 bases at this position.) Type 1 variant with reverse primer: 5'-CTAAGGAAACCCCAGAATGC-3' (Serial Number 3) Type 2 variant with forward primer: 5'-CTTCTTTGGACTGTATAGAGACT-3' (Serial Number 4) Type 2 variant with reverse primer: 5'-GCCAAGCCCTAGATGCCT-3' (Serial Number 5) Type 3 variant with forward primer: 5'-GCTGCCCGGGGAGATTA-3' (Serial Number 6) Type 3 variant with reverse primer: 5'-AAGAACACATTATTTCCATACCAC-3' (Serial Number 7) Type 4 variant with forward primer: 5'-CTCTTGTTTTCAATTTATTTGAGG-3' (Serial Number 8) Type 4 variant with reverse primer: 5'-GGTGCCAGCCAGAGTTGT-3' (Serial Number 9) Type 5 variant with forward primer (1): 5'-TCTTGCTGGAGGCTGCAGA-3' (Serial Number 10) Type 5 variant with forward primer (2): 5'-CTTGCTGGAGGCTGCAGA-3' (Serial Number 11) Type 5 wild type using forward primer: 5'-ATTCTTGCTGGAGGCTGCGAA-3' (Serial Number 12) Type 5 variant with reverse primer (1): 5'-TAGGAAAAGCCGAGGTGCC-3' (Serial Number 13) Type 5 variant with reverse primer (2): 5'-GCCTGTCTAGGAAAAGCCG-3' (Serial Number 14) Type 19 variant with forward primer: 5'-TCCTCCCTTGGCAGCC-3' (Serial Number 15) Type 19 variant with reverse primer: 5'-AATGTAGAACCATCGCTGTAGC-3' (Serial Number 16) RNaseP uses forward primers: 5'-GCGGAGGGAAGCTCATCA-3' (Serial No. 17) RNaseP uses reverse primers: 5'-GTCTGACCTCGCGCGGA-3' (Serial Number 18) (a-2) Probes for detecting different variants of the SLC25A13 gene As probes for confirming the amplification of various variant types of the SLC25A13 gene, the following fluorescently labeled detection probes were synthesized by Primetech. In this embodiment, as combination (1), pairs of variant type 1, type 2 and type 5 (combination), and pairs of type 3, type 4 and type 19 (combination) were selected. As combination (2), pairs of type 2 and type 19, type 3 and type 4, and type 1 and type 5 were selected, and two or three fluorescent dyes were assigned to each pair. In addition, as combination (3), one fluorescent dye was selected for the classification detection of variant type 1 and wild type. It should be noted that only the base sequence portion of each probe is described in the sequence listing.

[0086] Type 1 variant with fluorescently labeled probe (1): 5'-X 1 -AGAGGCAGGTGAGCAAAGAGGAG-Q 2 -3' (base sequence portion: sequence number 19) Type 1 variant with fluorescently labeled probe (2): 5'-X 2- AGAGGCAGGTGAGCAAAGAGGAG-Q 1 -3' (base sequence portion: sequence number 19) Type 2 variant with fluorescently labeled probe: 5'-X 1 -CCTGACATGAATTAGCAAGACTGCG-Q 2 -3' (base sequence portion: sequence number 20) Type 3 variant with fluorescently labeled probe: 5'-X 3 -TGGCCAAACCACTTACAGCG-Q 2 -3' (base sequence portion: sequence number 21) Type 4 variant with fluorescently labeled probe: 5'-X3 -CGCTCCTTAACAACATGGAACTCATTAG-Q 2 -3' (base sequence portion: sequence number 22) Type 5 variant with fluorescently labeled probe (1): 5'-X 1 -TTAACCACAGATCCTGCACAAGGG-Q 2 -3' (base sequence portion: sequence number 23) Type 5 variant with fluorescently labeled probe (2): 5'-X 2 -TTAACCACAGATCCTGCACAAGGG-Q 1 -3' (base sequence portion: sequence number 23) Type 5 variant with fluorescently labeled probe (3): 5'-X 3 -TTAACCACAGATCCTGCACAAGGG-Q 1 -3' (base sequence portion: sequence number 23) Type 19 variant with fluorescently labeled probe (1): 5'-X 3 -CCGCCCCCGATTTCTCCA-Q 2 -3' (base sequence portion: sequence number 24) Type 19 variant with fluorescently labeled probe (2): 5'-X 1 -CCGCCCCCGATTTCTCCA-Q 2 -3' (base sequence portion: sequence number 24) RNaseP fluorescent detection probe: 5'-X 4 -CCACGAGCTGAGTGCGTCCTG-Q 1 -3' (base sequence portion: sequence number 25) Here, the symbols in the above sequence are described as follows.

[0087] X 1 It utilizes the labeling sites of a fluorescent substance (Quasar (registered trademark) 670).

[0088] X 2 It utilizes the labeling sites of a fluorescent substance (CAL Fluor (registered trademark) Orange 560).

[0089] X 3It utilizes the labeling sites of a fluorescent substance (CAL Fluor (registered trademark) Red610).

[0090] X 4 It utilizes fluorescent material (FAM) labeling sites.

[0091] Q 1 It utilizes the marker site of the quencher (BHQ (registered trademark)-1).

[0092] Q 2 It utilizes the marker site of the quencher (BHQ (registered trademark)-2).

[0093] All of the fluorescent dyes and quenchers (matting agents) mentioned above were manufactured by LGC Biosearch Technologies.

[0094] (a-3) plasmid To quantify the PCR amplification products, partial gene sequences of various variants (wild-type and mutant) of the SLC25A13 gene, corresponding to those shown below, were integrated into vectors. The resulting plasmids were synthesized by Eurofins Genomics (Tokyo, Japan) and used as variant negative and positive controls. In the sequences of the plasmids below, uppercase letters represent exon sequences and lowercase letters represent intron sequences.

[0095] Type 1 variant plasmid (sequence number 26): gagaaaaagaagccaaactgaaggctatactgaaatatgagaaatgaaaaaagggatgtttttaaattttataatgtaaattgtaataaattggtatatttgttgcttgtgtttgtttttcccctacagAC (4bpdel) GACCTTAGCAGACATTGAACGGATTGCTCCTCTGGAAGAGGGA ACTCTGCCCTTTAACTTGGCTGAGGCCCAGAGGCAGgtgagcaaagaggagcaaacttgcattctggggtttccttagcaggatacccccaaccctgttccacttgcagttgcctttgcggcattggtatctgacttaaccatttttctgttttgcaccaaaactctcgataaattttaaaagg It should be noted that (4bpdel) indicates that 4 bases are missing at this position.

[0096] Type 1 wild-type plasmid (serial number 27): gagaaaaagaagccaaactgaaggctatactgaaatatgagaaatgaaaaaagggatgtttttaaattttataatgtaaattgtaataaattggtatatttgttgcttgtgtttgtttttcccctacagACGTATGACCTTAGCAGACATTGAACGGATTGCTCCTCTGGAAGAGGGAACTCTGCCCTTTAACTTGGCTGAGGCCCAGAGGCAGgtgagcaaagaggagcaaacttgcattctggggtttccttagcaggataccccaaccctgttccacttgcagttgcctttgcggcattggtatctgacttaaccatttttctgttttgcaccaaaactctcgataaattttaaagg Type 2 variant plasmid (Sequence No. 28): CTGTTGGAGCCACTGCTGTGTATCCTATCGATCTTGTAAAAACTCGAATGCAGAACCAACGATCAACTGGCTCTTTTGTGGGAGAACTCATGTATAAAAACAGCTTTGACTGTTTTAAGAAAGTGCTACGCTATGAAGGCTTCTTTGGACTGTATAGAGattagtgccacatgctcaatacctgttaggtgaaataacactcaaaggtttggtttctcatcttagtgcctgacatgaattagcaagactgcgttaaaatggaaatacagcagattttcaattatccatgctaatgggagtaggctggaggcatctagggcttggctaa It should be noted that the "a" at position 160 is an SNP site.

[0097] Type 3 variant plasmid (Sequence No. 29): ggacagcaaaataggcattttattgaatcggatttttaactttctttccacggccagcagttcaaagcacagttattttatatagtgagaatgtgaccagactgagatggtgttgtgtctctcctgcagGTATGCCTGCAGCATCTTTAGTGACCCCTGCTGATGTTATCAAGACGAGATTACAGGTGGCTGCCCG GGGAGATTACAGGTGGCTGCCCGGGCTGGCCAAACCACTTACAGCGGAGTGATAGACTGCTTTAGAAAGATACTGCGTGAAGAAGGACCAAAAGCTCTGTGGAAGGGAGCTGGTGgtatggaaataatgtgttcttaactctttggtatcaggtaaatttttaaaatatctaattatatctgtgatttctccat It should be noted that the sequence from position 201 to 222 is a repeating sequence.

[0098] Type 4 variant plasmid (sequence number 30): cttctctcttgttttcaatttatttgagGCTGCTGGAGGTACCACATCCCATCAAGTTAGTTTCTCCTATTTTAATGGATTTAATTCGCTCCTTAACAACATGGAACTCATTAGAAAGATCTATAGAACTCTGGCTGGCACCAGGAAA GATGTTGAAGTGACTAAGGgtgagtgagaatatatctgaattctagcctgcaagtattgtggtgtattattattagggtgaagaaggcaactagtactttattatttttctatcccattgacacatattaactatatgataacgtgtg It should be noted that the "A" at position 127 is an SNP site.

[0099] Type 5 variant plasmid (sequence number 31): tagcatatattgacagatgcatatttataagtgtttaatgactttctttatatttttcatcagcttctataaatatttttcttcaagGTGAACGATTTTGTGAGGGATAAATTTATGCACAAAGATGGTTCGGTCCCACTTGCAGCAGAAATTCTTGCTGGAGGCTGCataagtaccttttgaagctctcttcattgaaaagacttgtttcacatatatatcactaccatggtcaacaggtgtggactaaggcttctgtttaaccacagatcctgcacaagggcagagtctactagggcacctcggcttttcctagacaggcgaaccattccagaggtggaagggtaaatgtttctgaccttactgcctgttaagtcatgcctgt It should be noted that the "a" at position 169 is an SNP site.

[0100] Type 5 wild-type plasmid (SEQ ID NO: 32): tagcatatattgacagatgcatatttataagtgtttaatgactttctttatatttttcatcagcttctataaatatttttcttcaagGTGAACGATTTTGTGAGGGATAAATTTATGCACAAAGATGGTTCGGTCCCACTTGCAGCAGAAATTCTTGCTGGAGGCTGCgtaagtaccttttgaagctctcttcattgaaaagacttgtttcacatatatatcactaccatggtcaacaggtgtggactaaggcttctgtttaaccacagatcctgcacaagggcagagtctactagggcacctcggcttttcctagacaggcgaaccattccagaggtggaagggtaaatgtttctgaccttactgcctgttaagtcatgcctgt Type 19 variant (mutant) plasmid (SEQ ID NO: 33): gagcccgaacccctttccactgccaacacctcacctcgcccccgccgccatcttcctcctcccttggcagccccgcccccgatttctccatttttttaaagCTCGGTATTTCGATCCTCACCCCAGTTTGGTGTAACTTTGCTGACTTACGAATTGCTACAGCGATGGTTCTACATTGATTTTGG AGGAGTgtaagtatcatgctaaatctgctgctaaattttggctgctgctaatgctctgttgtcgtagggaaaggtacctcagtctagtctcttaataaaatagaagagatttagggaaatgttgaaattgtgttaacaaggtcatttccaaggggaacatacaactgatgagaatgtatcaactcc It should be noted that the sequence from 1 to 80 is the insertion part.

[0101] Partial sequence of RNaseP gene (Sequence No. 34): ATAGGCGGAGGGAAGCTCATCAGTGGGGCCACGAGCTGAGTGCGTCCTGTCACTCCACTCCCATGTCCCTTGGGAAGGTCTGAGACTAGGGCCAGAGGCGGCCCTAACAGGGCTCTCCCTGAGCTTCGGGGAGGTGAGTTCCCAGAGAACGGGGCTCCGCGCGAGGTCA GACTGGGCAGGAGATGCCGTGGACCCCGCCCTTCGGGGAGGGGCCCGGCGGATGCCTCCTTTGCCGGAGCTTGGAACAGACTCACGGCCAGCGAAGTGAGTTCAATGGCTGAGGTGAGGTACCCCGCAGGGGACCTCATAACCCAATTCAGACTACTCTCCTCCGCCCATT (b) PCR reagents used in combination (1) Prepare a PCR reagent comprising the following components using the following PCR buffer and enzyme "BIOTAQ HS DNA Polymerase" from "Ampdirect Plus Enzyme Kit" manufactured by Shimadzu Corporation.

[0102] PCR buffer (Ampdirect Plus) 0.03U / m L BIOTAQ (registered trademark) HS DNA polymerase 0.8 m M (final concentration) type 1 variant with forward primer 0.8 m M (final concentration) type 1 variant with reverse primer 0.5 m M (final concentration) type 2 variant with forward primer 0.5 m M (final concentration) type 2 variant with reverse primer 0.35 m M (final concentration) type 3 variant using forward primer 0.35 m M (final concentration) type 3 variant with reverse primer 1.0 m M (final concentration) type 4 variant with forward primer 1.0 m M (final concentration) type 4 variant with reverse primer 1.0 m M (final concentration) type 5 variant with forward primer (1) 1.0 m M (final concentration) type 5 variant with reverse primer (1) 0.35 m M (final concentration) type 19 variant using forward primer 0.35 m M (final concentration) type 19 variant with reverse primer 0.1 m M (final concentration) RNase P using forward primer 0.1 m M (final concentration) RNaseP using reverse primer 0.15 m M (final concentration) type 1 variant with fluorescently labeled probe (1) 0.1 m M (final concentration) type 2 variant with fluorescently labeled probe 0.15 m M (final concentration) type 3 variant with fluorescently labeled probe 0.06 m M (final concentration) type 4 variant with fluorescently labeled probe 0.15 m M (final concentration) type 5 variant with fluorescently labeled probe (1) 0.030 m M (final concentration) type 19 variant with fluorescently labeled probe (1) 0.04 m M (final concentration) RNaseP detection probe (c) Preparation and determination of reactivity of each variant using control dried filter paper blood for confirmation. Human erythrocyte fractions (100%) with leukocytes removed were combined with a variant plasmid and an RNase P plasmid (33333 copies / mL). m L) Mix in a 6:4 mass ratio, and then permeate the resulting mixture into filter paper at a depth of 40 mm. m L and let it dry. From the dried filter paper blood section, collect Φ1.5mm perforated slides and place them in PCR reaction tubes, then add 40 m The PCR reagents of L described in (b) above were used to confirm the specificity of each variant type by real-time PCR under the following PCR reaction conditions.

[0103] (d) Conditions for PCR reaction 1) 95℃: 15 minutes 2) 95℃: 15 seconds, 63℃: 80 seconds (45 cycles) 3) 37℃: 5 minutes (e) Equipment Thermal circulator equipment: "LightCycler 96 System" (Roche) (f) Analysis of amplification curves The obtained amplification curves are expressed according to each measurement wavelength (Cy5, Red610) set in the above-mentioned equipment. Figure 1 and Figure 2 (Examples 1 and 2).

[0104] like Figure 1 As shown, the shape and rise characteristics of the amplification curves of variants of type 1, type 2, and type 5 detected at the same fluorescence wavelength (Cy5) were compared under the same template amount (10000 copies / reaction). The Cq value of variant type 1 was calculated to be 28.2, while the Cq values ​​of variants type 2 and type 5 were calculated to be 35.3 and 38.1, respectively, showing a difference of more than 5 cycles. On the other hand, the fluorescence value (RFU) of variant type 2 at the 45th cycle was 0.190, and the fluorescence value (RFU) of variant type 5 was 0.345, with a type 2 to type 5 ratio of 1.8. Therefore, with Figure 1With the Cq value obtained as the center value and its range set to ±2, the Cq value range for variant 1 is 26.2–30.2, and the Cq value range for variant 2 is 33.3–37.3, with their ranges not overlapping. On the other hand, with the fluorescence value (RFU) at the 45th cycle as the center value and the range width set to ±25%, the fluorescence value range for variant 2 is 0.143–0.238, and the fluorescence value range for variant 5 is 0.259–0.431, with their ranges not overlapping.

[0105] Based on the above results, the Type 1 variant can be distinguished from the Type 2 or Type 5 variant by setting the Cq value range. Furthermore, the Type 2 and Type 5 variants can be distinguished by setting the range of fluorescence values ​​(RFU) at the 45th cycle.

[0106] like Figure 2 As shown, the shape and rise characteristics of the amplification curves of variants 3, 4, and 19, detected at the same fluorescence wavelength (Red 610), were compared under the same template amount (10,000 copies / reaction). The Cq value of variant 4 was calculated to be 34.3, while the Cq values ​​of variants 3 and 19 were both calculated to be 26.8, showing a difference of more than 5 cycles. On the other hand, at the 45th cycle, the fluorescence value (RFU) of variant 3 was 1.70, and the fluorescence value (RFU) of variant 19 was 0.596, with a type 3 to type 19 ratio of 2.85. Therefore, with... Figure 2 With the Cq value obtained as the center value and its range set to ±2, the Cq value range of variant 4 is 32.3 to 36.3, while the Cq value ranges of variants 3 and 19 are the same, from 24.8 to 28.8, and their ranges do not overlap. On the other hand, with the range width centered on the fluorescence value (RFU) of the 45th cycle set to ±40%, the fluorescence value range of variant 3 is 1.02 to 2.38, and the fluorescence value range of variant 19 is 0.358 to 0.834, and their ranges do not overlap.

[0107] Based on the above results, for the type 4 variant, it is possible to distinguish it from the type 3 or type 19 variant by setting the range of Cq values. Furthermore, for the type 3 and type 19 variants, it is possible to distinguish them by setting the range of fluorescence values ​​(RFU) at the 45th cycle.

[0108] (g) PCR reagents used in combination (2) Prepare a PCR reagent comprising the following components using the following PCR buffer and enzyme "BIOTAQ HS DNA polymerase" from the "Ampdirect Plus Enzyme Kit" manufactured by Shimadzu Corporation. It should be noted that, in order to terminate real-time PCR midway, the concentrations of fluorescently labeled probes of types 1, 3, and 19 are set to be lower than the concentrations of fluorescently labeled probes of types 2, 4, and 5.

[0109] PCR buffer (Ampdirect Plus) 0.03U / m L BIOTAQ (registered trademark) HS DNA polymerase 0.35 m M (final concentration) type 1 variant with forward primer 0.35 m M (final concentration) type 1 variant with reverse primer 0.17 m M (final concentration) type 2 variant with forward primer 0.17 m M (final concentration) type 2 variant with reverse primer 0.35 m M (final concentration) type 3 variant using forward primer 0.35 m M (final concentration) type 3 variant with reverse primer 0.2 m M (final concentration) type 4 variant with forward primer 0.2 m M (final concentration) type 4 variant with reverse primer 0.6 m M (final concentration) type 5 variant with forward primer (1) 0.6 m M (final concentration) type 5 variant with reverse primer (1) 0.35 m M (final concentration) type 19 variant using forward primer 0.35 m M (final concentration) type 19 variant with reverse primer 0.125 m M (final concentration) RNase P using forward primer 0.125 m M (final concentration) RNaseP using reverse primer 0.035 m M (final concentration) type 1 variant with fluorescently labeled probe (2) 0.1 mM (final concentration) type 2 variant with fluorescently labeled probe 0.035 m M (final concentration) type 3 variant with fluorescently labeled probe 0.15 m M (final concentration) type 4 variant with fluorescently labeled probe 0.15 m M (final concentration) type 5 variant with fluorescently labeled probe (2) 0.025 m M (final concentration) type 19 variant with fluorescently labeled probe (2) 0.04 m M (final concentration) RNaseP detection probe (h) Preparation and determination of reactivity of each variant using control dried filter paper blood for confirmation. Human erythrocyte fractions (100%) with leukocytes removed were combined with a variant plasmid and an RNase P plasmid (33333 copies / mL). m L) Mix in a 6:4 mass ratio, and then permeate the resulting mixture into filter paper at a depth of 40 mm. m L and let it dry. From the dried filter paper blood section, collect Φ1.5mm perforated slides and place them in PCR reaction tubes, then add 40 m The PCR reagents of L (g) were used to confirm the specificity of each variant type by real-time PCR under the following PCR reaction conditions. Furthermore, in order to confirm the detection of two variant types at one fluorescence wavelength, plasmid mixtures of each pair of type 2 and type 19, type 1 and type 5, and type 3 and type 4 were prepared and used for the reaction.

[0110] (i) Conditions for PCR reaction 1) 95℃: 15 minutes 2) 95℃: 15 seconds, 63℃: 80 seconds (45 cycles) 3) 37℃: 5 minutes (j) Equipment Thermal circulator equipment: "LightCycler 96 System" (Roche) (k) Analysis of amplification curves The obtained amplification curves are expressed according to each measurement wavelength (Cy5, Red610, or Hex) set in the above-mentioned equipment. Figure 3~Figure 5 (Examples 3-5).

[0111] like Figure 3As shown, when comparing the shape and rise characteristics of the amplification curves of variants of type 2 and type 19 detected at the same fluorescence wavelength (Cy5) with the same template amount (10,000 copies / reaction), the Cq value of variant 2 was calculated to be 33.8, while that of variant 19 was calculated to be 27.7, with a difference observed for more than 5 cycles. On the other hand, at the 45th cycle, the fluorescence value (RFU) of variant 2 was 0.562, and the fluorescence value (RFU) of variant 19 was 0.275, with a type 2 to type 19 ratio of 2.0.

[0112] Therefore, in the Figure 3 The Cq values ​​obtained are center values. With their range set to ±2, the Cq value range of the type 2 variant is 31.8 to 35.8, and the Cq value range of the type 19 variant is 25.7 to 29.7. Their ranges do not overlap.

[0113] On the other hand, when the range width centered on the fluorescence value (RFU) of the 45th cycle is set to ±30%, the fluorescence value range of the type 2 variant is 0.393 to 0.731, and the fluorescence value range of the type 19 variant is 0.193 to 0.358, and their ranges do not overlap.

[0114] In contrast, assuming the coexistence of type 2 and type 19 variants, the plasmid mixture was measured, and the calculated Cq value was 27.4, which falls within the Cq value range of type 19 variant, thus indicating the presence of type 19 variant. Furthermore, the calculated fluorescence value at the 45th cycle was 0.562, which falls within the fluorescence value range of type 2 variant, thus also indicating the presence of type 2 variant. Therefore, it can be said that a complex heterozygote of type 2 and type 19 can be identified.

[0115] Figure 4 The same applies to types 3 and 4. Comparing the shape and rise characteristics of the amplification curves of each variant of type 3 and type 4 detected at the same fluorescence wavelength (Red 610) with the same template amount (10,000 copies / reaction), the Cq value of variant 3 was 28.7, while that of variant 4 was 35.0, confirming a difference of more than 5 cycles. Furthermore, the fluorescence value (RFU) of variant 3 at cycle 45 was 0.437, while that of variant 4 was 1.33, resulting in a ratio of 3.0 between type 4 and type 3.

[0116] Therefore, regarding the range of Cq values, Figure 4 The Cq values ​​obtained are center values. With their range set to ±2, the Cq value range of the type 3 variant is 26.7 to 30.7, and the Cq value range of the type 4 variant is 33.0 to 37.0, but their ranges do not overlap.

[0117] On the other hand, when the range width centered on the fluorescence value (RFU) of the 45th cycle is set to ±30%, the fluorescence value range of the type 3 variant is 0.306 to 0.568, and the fluorescence value range of the type 4 variant is 0.931 to 1.73, and their ranges do not overlap.

[0118] In contrast, assuming that type 3 and type 4 variants coexist, the plasmid mixture was measured, and the calculated Cq value was 30.1, which is within the Cq value range of type 3 variant, thus indicating the presence of type 3 variant. The calculated fluorescence value of 1.35 on the 45th cycle is within the fluorescence value range of type 4 variant, thus also indicating the presence of type 4 variant. Therefore, it can be said that a composite heterozygote of type 3 and type 4 can be identified.

[0119] and then, Figure 5 The same applies to Type 1 and Type 5. Comparing the shape and rise characteristics of the amplification curves of each variant of Type 1 and Type 5 detected at the same fluorescence wavelength (Hex), and using the same template amount (10,000 copies / reaction), the Cq value of variant Type 1 was 27.5, while that of variant Type 5 was 36.5, confirming a difference of more than 5 cycles. On the other hand, the fluorescence value (RFU) of variant Type 1 at cycle 45 was 0.480, while that of variant Type 5 was 1.32, resulting in a ratio of 2.75 between Type 5 and Type 1.

[0120] Therefore, regarding the range of Cq values, Figure 5 The Cq value obtained is the center value. With its range set to ±2, the Cq value range of the type 1 variant is 27.5 to 29.5, and the Cq value range of the type 5 variant is 34.5 to 38.5, but their ranges do not overlap.

[0121] On the other hand, when the range width centered on the fluorescence value (RFU) of the 45th cycle is set to ±40%, the fluorescence value range of the type 1 variant is 0.288 to 0.672, and the fluorescence value range of the type 5 variant is 0.792 to 1.85, and their ranges do not overlap.

[0122] In contrast, assuming that variants 1 and 5 coexist, the plasmid mixture was measured, and the calculated Cq value was 29.1, which is within the Cq value range of variant 1, thus indicating the presence of variant 1. The calculated fluorescence value of 1.78 on the 45th cycle is within the fluorescence value range of variant 4, thus also indicating the presence of variant 4. Therefore, it can be said that a complex heterozygote of variants 3 and 4 can be identified.

[0123] (l) PCR reagents used in combination (3) Using the following PCR buffer and enzyme, BIOTAQ HS DNA polymerase, from the "Ampdirect Plus Enzyme Kit" manufactured by Shimadzu Corporation, a PCR reagent containing the following components was prepared. It should be noted that the concentrations of the forward primer for the Type 1 variant and the primer for the wild type were set as follows: approximately twice the fluorescence value (RFU) of the variant and wild type at the 45th cycle when real-time PCR was terminated midway.

[0124] PCR buffer (Ampdirect Plus) 0.03U / m L BIOTAQ (registered trademark) HS DNA polymerase 0.05 m M (final concentration) type 1 variant with forward primer 0.09 m M (final concentration) Type 1 Wild-type uses forward primer 0.8 m M (final concentration) type 1 variant with reverse primer 0.6 m M (final concentration) type 1 variant with fluorescently labeled probe (2) The reverse primer for type 1 variant is also used as the reverse primer for type 1 wild type, and the fluorescently labeled probe for type 1 variant (2) is also used as the fluorescently labeled probe for type 1 wild type.

[0125] (m) Preparation and determination of reactivity of each variant using control dried filter paper blood for confirmation. Human erythrocyte fractions (100%) with leukocytes removed were respectively coupled with a type 1 variant plasmid and a type 1 wild-type plasmid (33333 copies / mL). m L), and plasmids obtained by pre-mixing the variant and wild type at a 1:1 ratio for use as a heterozygous variant of type 1, were mixed at a mass ratio of 6:4, and the resulting mixture was allowed to penetrate filter paper 40. m L and let it dry. Collect Φ1.5mm perforated slides from blood sections containing various types of dried filter paper and place them in PCR reaction tubes, then add 40 m The PCR reagents of L (l) described above were used to confirm the specificity of the variant type and wild type of type 1 by real-time PCR under the following PCR reaction conditions.

[0126] (n) Conditions for PCR reaction 1) 95℃: 15 minutes 2) 95℃: 15 seconds, 63℃: 80 seconds (45 cycles) 3) 37℃: 5 minutes (o) equipment Thermal circulator equipment: "LightCycler 96 System" (Roche) (p) Analysis of amplification curves The obtained amplification curve is shown in Figure 6 (Example 6).

[0127] like Figure 6 As shown, the difference in Cq values ​​between amplification using plasmids of type 1 variant and type 1 wild-type as templates was calculated to be 29.5 and 27.7, respectively, showing no significant difference. On the other hand, the fluorescence values ​​(RFU) of type 1 variant and wild-type in the 45th cycle were 0.348 and 0.570, respectively, and the fluorescence value of the heterozygous variant, calculated as an average of 0.850 when N=4, was 1.64 and 1.49, respectively. The fluorescence values ​​(RFU) of the heterozygous variant after four cycles ranged from 0.846 to 0.853, demonstrating excellent reproducibility.

[0128] Therefore, with the range width centered on the fluorescence value (RFU) of the 45th cycle set at ±15%, the fluorescence value ranges of the homozygous variant, wild type, and heterozygous variant of type 1 are 0.296–0.400, 0.485–0.656, and 0.723–0.978, respectively, and their ranges do not overlap.

[0129] Based on the above results, by setting the range of fluorescence values ​​(RFU) in the 45th cycle, it is possible to distinguish between the type 1 homozygous variant, the type 1 wild-type, and the type 1 heterozygous variant.

[0130] (q) PCR reagents used in combination (4) Prepare a PCR reagent comprising the following components using the following PCR buffer and enzyme "BIOTAQ HS DNA polymerase" from the "Ampdirect Plus Enzyme Kit" manufactured by Shimadzu Corporation. It should be noted that the concentration of the primers used for Type 5 wild-type PCR is set to a lower concentration than that used for the variant when real-time PCR is terminated midway.

[0131] PCR buffer (Ampdirect Plus) 0.03U / m L BIOTAQ (registered trademark) HS DNA polymerase 0.15 m M (final concentration) type 5 variant with forward primer (2) 0.025 m M (final concentration) type 5 wild type using forward primer 0.35 m M (final concentration) type 5 variant with reverse primer (2) 0.2 m M (final concentration) type 5 variant with fluorescently labeled probe (3) The reverse primer (2) for type 5 variant is also used as the reverse primer for type 5 wild type, and the fluorescently labeled probe (3) for type 5 variant is also used as the fluorescently labeled probe for type 5 wild type.

[0132] (r) Confirmation of reactivity of each variant using preparation and determination of control dried filter paper blood Human erythrocyte fractions (100%) with leukocytes removed were respectively coupled with a type 5 variant plasmid and a type 5 wild-type plasmid (33333 copies / ). m L), and plasmids obtained by pre-mixing the variant and wild type at a 1:1 ratio for use as a heterozygous variant of type 5, were mixed at a mass ratio of 6:4, and the resulting mixture was impregnated into filter paper 40. m L and allow it to dry. Collect Φ1.5mm perforated slides from blood sections containing various types of dried filter paper and place them in PCR reaction tubes. Add 40g of the PCR reagent described above (q). m L, under the following PCR reaction conditions, confirmed the specificity of variant type 5 and wild type by real-time PCR.

[0133] (s) Conditions for PCR reaction 1) 95℃: 15 minutes 2) 95℃: 15 seconds, 63℃: 80 seconds (55 cycles) 3) 37℃: 5 minutes (t) equipment Thermal circulator equipment: "LightCycler 96 System" (Roche) (u) Analysis of amplification curves The obtained amplification curves are respectively shown in... Figure 7 (Example 7).

[0134] like Figure 7 As shown, the Cq values ​​of amplification using plasmids of the type 5 homozygous variant and the type 5 wild-type as templates were calculated to be 39.3 and 33.8, respectively, confirming a difference of more than 5 cycles. On the other hand, the fluorescence values ​​(RFU) of the type 5 homozygous variant and the wild-type at the 55th cycle were 4.38 and 2.99, respectively, with a type 5 homozygous variant to wild-type ratio of 1.46.

[0135] Therefore, regarding the range of Cq values, Figure 7With the Cq values ​​obtained as center values ​​and their range set to ±2, the Cq values ​​of the homozygous type 5 variant range from 37.3 to 41.3, and the Cq values ​​of the wild type 5 variant range from 31.8 to 35.8, but their ranges do not overlap. Furthermore, with the fluorescence value (RFU) at the 55th cycle as the center width set to ±15%, the fluorescence value ranges of the homozygous type 5 variant and the wild type are 3.72 to 5.04 and 2.54 to 3.44, respectively, and their ranges do not overlap.

[0136] On the other hand, the Cq value of the type 5 heterozygous variant was 35.1, which, since it falls within the range of wild-type Cq values, suggests the presence of a wild-type. Additionally, the fluorescence value (RFU) at cycle 55 was 4.30, which, since it falls within the range of homozygous variants, also suggests the presence of a variant. Combining these two results allows for the differentiation of the type 5 homozygous variant, heterozygous variant, and wild-type.

[0137] (v) PCR reagents used in combination (5) A PCR reagent comprising the following components was prepared using the PCR buffer and the enzyme BIOTAQ HS DNA polymerase from the "Ampdirect Plus Enzyme Set" manufactured by Shimadzu Corporation. In this assay system, primer set (1) used in Example 4 and primer set (2) used in Example 6 were combined.

[0138] PCR buffer (Ampdirect Plus) 0.03U / m L BIOTAQ (registered trademark) HS DNA polymerase 0.05 m M (final concentration) type 1 variant with forward primer 0.09 m M (final concentration) Type 1 Wild-type uses forward primer 0.8 m M (final concentration) type 1 variant with reverse primer 0.35 m M (final concentration) type 3 variant using forward primer 0.35 m M (final concentration) type 3 variant with reverse primer 0.2 m M (final concentration) type 4 variant with forward primer 0.2 m M (final concentration) type 4 variant with reverse primer 0.125 m M (final concentration) RNase P using forward primer 0.125 m M (final concentration) RNaseP using reverse primer 0.6 m M (final concentration) type 1 variant with fluorescently labeled probe (2) 0.035 m M (final concentration) type 3 variant with fluorescently labeled probe 0.15 m M (final concentration) type 4 variant with fluorescently labeled probe 0.04 m M (final concentration) RNaseP detection probe The reverse primer for type 1 variant is also used as the reverse primer for type 1 wild type, and the fluorescently labeled probe for type 1 variant (2) is also used as the fluorescently labeled probe for type 1 wild type.

[0139] (w) Confirmation of reactivity of each variant using preparation and determination of control dried filter paper blood. The dried filter paper blood prepared in Examples 4 and 6 was used in this assay using the same procedure.

[0140] (x) Conditions for PCR reaction 1) 95℃: 15 minutes 2) 95℃: 15 seconds, 63℃: 80 seconds (45 cycles) 3) 37℃: 5 minutes (y) equipment Thermal circulator equipment: "LightCycler 96 System" (Roche) (z) Analysis of amplification curves The obtained amplification curve is shown in Figure 8 and Figure 9 (Example 8).

[0141] Figure 8 The amplification curves of each type of type 1 shown are the same as those shown in Example 6. Figure 6 The results were the same. Measured simultaneously. Figure 9 The amplification curves of types 3 and 4 shown are also consistent with those shown in Example 4. Figure 4 The results were the same. This confirms that primer set (1) and primer set (2) can also be combined.

[0142] Thus, it has been confirmed that by using the discrimination method of the present invention, it is also possible to distinguish between variants, compound variants, and wild types in measurements based on the same fluorescence wavelength.

Claims

1. A method for identifying target nucleic acids, characterized in that, The method comprises: step (a) below; and (b) to (c) and / or (d) to (e) below, wherein the discrimination method uses simultaneous multiplex real-time PCR to distinguish between two or more target nucleic acids contained in a sample. (a) A process of bringing the sample, primer set and fluorescently labeled probe into contact to amplify the target nucleic acid in the sample; (b) The process of generating an amplification curve based on step (a) and obtaining the Ct value from a set threshold; (c) A step of comparing the Ct value set for each of the target nucleic acids with the Ct value obtained in step (b); (d) The process of generating an amplification curve based on step (a) to obtain fluorescence values ​​within a set number of cycles; (e) A step of comparing the fluorescence value within a set number of cycles for each target nucleic acid with the fluorescence value obtained in step (d).

2. The discrimination method according to claim 1, wherein, The discrimination method uses two or more primer sets (1) as the primer sets, the primer sets (1) comprising a forward primer and a reverse primer, and / or uses one or more primer sets (2) as the primer sets, the primer sets (2) comprising at least one of two or more forward primers and reverse primers, and one or more of the other.

3. The discrimination method according to claim 2, wherein, The discrimination method uses two or more primer sets (1) as primer sets and uses two or more fluorescently labeled probes labeled with the same fluorescent label as fluorescently labeled probes.

4. The discrimination method according to claim 2, wherein, The discrimination method uses one or more primer sets (2) as the primer set and one or more fluorescently labeled probes as the fluorescently labeled probes.

5. The discrimination method according to any one of claims 1 to 4, wherein, The process (a) is carried out in the same container.

6. The discrimination method according to any one of claims 1 to 5, wherein, The fluorescently labeled probes are designed to hold the target nucleic acids.

7. The discrimination method according to any one of claims 1 to 6, wherein, When setting the Ct value for each target nucleic acid in step (c), the difference between the center values ​​of each Ct value range under the same template amount is greater than 5, and the Ct value ranges do not overlap.

8. The discrimination method according to any one of claims 1 to 7, wherein, When setting the fluorescence value for each target nucleic acid within a set number of cycles in step (e), the ratio of the center values ​​of each fluorescence value range is greater than 1.4 times, and the fluorescence value ranges under the set number of cycles do not overlap.

9. The discrimination method according to any one of claims 1 to 8, wherein, The two or more target nucleic acids comprise at least one selected from combinations of gene variants that are distinct from each other, including deletion mutations, insertion mutations, and point mutations, and combinations of a first gene variant and the wild type of that first gene variant.

10. The discrimination method according to any one of claims 1 to 9, wherein, The sample used in step (a) is a sample of blood slices obtained by directly using filter paper without pretreatment, wherein the blood is obtained by drying the filter paper after it contains blood.

11. The discrimination method according to any one of claims 1 to 10, wherein, The fluorescently labeled probe has fluorescent substance sites and quencher sites, and contains a partial sequence complementary to the template for the nucleic acid amplification reaction. The discrimination method detects the amplified target nucleic acid by detecting the fluorescence generated when the fluorescent material site is irradiated with excitation light.